NEW YORK (GenomeWeb) – HTG Molecular Diagnostics announced yesterday that it has signed a master companion diagnostics development agreement with Merck KGaA, which will initially focus on a test for use with the German drugmaker's investigational Bruton's tyrosine kinase (BTK) inhibitor M7583.

BTK is an enzyme associated with B cell development and implicated in certain autoimmune diseases and cancers. Merck is developing M7583 as a treatment for B cell lymphoma and expects to begin clinical testing of the drug this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.